. 2019 Jun 5;60(8):1449–1456. doi: 10.1194/jlr.P091033

TABLE 1.

Demographic data and diagnostic parameters of studied subjects

	Controls (n = 39)	AD (n = 37)	non-AD DEM (n = 16)	P
Age (years)	60 ± 16	69 ± 9^a	63 ± 8	^aP < 0.01 vs. controls
Males [n (%)]	20 (51)	19 (49)	8 (50)	0.960
Aβ 1-42 (ng/l)	966 (782–1,390)	472 (381–562)^a	742 (555–1,414)	^aP < 0.0001 vs. controls and non-AD DEM
Total tau (ng/l)	120 (98–181)	607 (297–978)^a,b	216 (103–549)	^aP < 0.0001 vs. controls
Total tau (ng/l)	120 (98–181)	607 (297–978)^a,b	216 (103–549)	^bP = 0.004 vs. non-AD DEM
Phosphorylated tau (ng/l)	30 (26–38)	84 (62–104)^a	34 (16–50)	^aP < 0.0001 vs. controls and non-AD DEM
apoE4 carriers [n (%)]	7 (18)	26 (70)^a	5 (31)	^aP < 0.0001 vs. controls and non-AD DEM

Normally distributed parameters are presented as means ± SDs, and skewed continuous parameters are expressed as medians (interquartile ranges). Statistically different values are reported in bold. CSF neurobiomarker (Aβ 1-42, total tau, and phosphorylated tau) values were available for 12/39 subjects in the control group and 13/16 subjects in the non-AD DEM group.